What duration of intravenous antibiotic therapy should be used in the treatment of infective exacerbations of cystic fibrosis in patients chronically colonised with Pseudomonas aeruginosa? - Duration of antibiotics in infective exacerbations of cystic fibrosis

Imperial College, London0 个研究点目标入组 240 人开始时间: 2010年10月14日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Confirmed diagnosis of cystic fibrosis (sweat test and/or gene typing). All patients attending the adult CF unit for treatment for an infective exacerbation of cystic fibrosis caused by Pseudomonas aeruginosa.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patients will be excluded from the study if any of the following apply: -unable to give consent -allergy to tobramycin and/or both meropenem and ceftazidime -intolerance of aminoglycoside antibiotics -Pseudomonas resistant to both meropenem and ceftazidime. -on the active transplant list or baseline FEV1 <20% predicted -pregnancy or breast-feeding -co-existent active allergic bronchopulmonary aspergillosis requiring a change in steroid or antifungal therapy -co-existent mycobacterial infection -a previous participant in this study No patient will be excluded on the basis of disability (unless their disability is such to prevent them giving proper informed consent), gender, race, ethnic origin or nationality, religion or belief, or sexual orientation.

发起方